Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent
- Autores
- Mansilla, Eduardo; Martínez, Ricardo Rangel; Marin, Gustavo Horacio; Filho, Idiberto Zotarelli; Rivas, Elsa; Rivas, Jaime; Carvalho, Katherine Athayde Teixeira de; Dayer, Mohammad Reza; Samadikuchaksaraei, Alí
- Año de publicación
- 2020
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- SARS-CoV-2 is a novel RNA coronavirus responsible of a deadly pandemic: the clinical illness COVID-19. With only one authorized drug for emergency use in critically ill patients: Remdesivir, there is not any other approved drug or vaccine yet with proven potential to overcome this infection. We exposed here many scientific evidences to support our novel idea that a macrolide, basically Clarithromycin, could be effective as a single agent for treatment and prophylaxis of COVID-19. Clarithromycin could change the history of this pandemic. It could reduce the costs of treatment and the potential adverse effects when combining more than one drug such as with Hydroxychloroquine. Clarithromycin treatment and prophylaxis as a single agent could be much more simple, safe and cheaper as giving Chloroquine or Hydroxychloroquine alone or in combination with Azithromycin as well as other therapeutic options.
Fil: Mansilla, Eduardo. Universidad Nacional de La Plata. Facultad de Ciencias Médicas; Argentina
Fil: Martínez, Ricardo Rangel. ExomePharma; México
Fil: Marin, Gustavo Horacio. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de La Plata. Facultad de Ciencias Médicas; Argentina
Fil: Filho, Idiberto Zotarelli. Faceres Medical School; Brasil
Fil: Rivas, Elsa. Hospital de la Amistad Perú - Corea San Rosa II; Perú
Fil: Rivas, Jaime. Hospital de la Amistad Perú - Corea San Rosa II; Perú
Fil: Carvalho, Katherine Athayde Teixeira de. Research Institute Pelé Little Prince; Brasil
Fil: Dayer, Mohammad Reza. Shahid Chamran University of Ahvaz; Irán
Fil: Samadikuchaksaraei, Alí. Iran University of Medical Sciences; Irán - Materia
-
Antibiotics
COVID-19
Macrolides - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/108870
Ver los metadatos del registro completo
id |
CONICETDig_4d0804cbf3fe04efd318ef3115957d23 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/108870 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single AgentMansilla, EduardoMartínez, Ricardo RangelMarin, Gustavo HoracioFilho, Idiberto ZotarelliRivas, ElsaRivas, JaimeCarvalho, Katherine Athayde Teixeira deDayer, Mohammad RezaSamadikuchaksaraei, AlíAntibioticsCOVID-19Macrolideshttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3SARS-CoV-2 is a novel RNA coronavirus responsible of a deadly pandemic: the clinical illness COVID-19. With only one authorized drug for emergency use in critically ill patients: Remdesivir, there is not any other approved drug or vaccine yet with proven potential to overcome this infection. We exposed here many scientific evidences to support our novel idea that a macrolide, basically Clarithromycin, could be effective as a single agent for treatment and prophylaxis of COVID-19. Clarithromycin could change the history of this pandemic. It could reduce the costs of treatment and the potential adverse effects when combining more than one drug such as with Hydroxychloroquine. Clarithromycin treatment and prophylaxis as a single agent could be much more simple, safe and cheaper as giving Chloroquine or Hydroxychloroquine alone or in combination with Azithromycin as well as other therapeutic options.Fil: Mansilla, Eduardo. Universidad Nacional de La Plata. Facultad de Ciencias Médicas; ArgentinaFil: Martínez, Ricardo Rangel. ExomePharma; MéxicoFil: Marin, Gustavo Horacio. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de La Plata. Facultad de Ciencias Médicas; ArgentinaFil: Filho, Idiberto Zotarelli. Faceres Medical School; BrasilFil: Rivas, Elsa. Hospital de la Amistad Perú - Corea San Rosa II; PerúFil: Rivas, Jaime. Hospital de la Amistad Perú - Corea San Rosa II; PerúFil: Carvalho, Katherine Athayde Teixeira de. Research Institute Pelé Little Prince; BrasilFil: Dayer, Mohammad Reza. Shahid Chamran University of Ahvaz; IránFil: Samadikuchaksaraei, Alí. Iran University of Medical Sciences; IránScientific Research2020-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/108870Mansilla, Eduardo; Martínez, Ricardo Rangel; Marin, Gustavo Horacio; Filho, Idiberto Zotarelli; Rivas, Elsa; et al.; Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent; Scientific Research; Pharmacology & Pharmacy; 11; 6; 6-2020; 85-1042157-9423CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.4236/pp.2020.116009info:eu-repo/semantics/altIdentifier/url/https://www.scirp.org/journal/paperinformation.aspx?paperid=100971info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:46:43Zoai:ri.conicet.gov.ar:11336/108870instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:46:44.19CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent |
title |
Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent |
spellingShingle |
Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent Mansilla, Eduardo Antibiotics COVID-19 Macrolides |
title_short |
Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent |
title_full |
Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent |
title_fullStr |
Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent |
title_full_unstemmed |
Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent |
title_sort |
Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent |
dc.creator.none.fl_str_mv |
Mansilla, Eduardo Martínez, Ricardo Rangel Marin, Gustavo Horacio Filho, Idiberto Zotarelli Rivas, Elsa Rivas, Jaime Carvalho, Katherine Athayde Teixeira de Dayer, Mohammad Reza Samadikuchaksaraei, Alí |
author |
Mansilla, Eduardo |
author_facet |
Mansilla, Eduardo Martínez, Ricardo Rangel Marin, Gustavo Horacio Filho, Idiberto Zotarelli Rivas, Elsa Rivas, Jaime Carvalho, Katherine Athayde Teixeira de Dayer, Mohammad Reza Samadikuchaksaraei, Alí |
author_role |
author |
author2 |
Martínez, Ricardo Rangel Marin, Gustavo Horacio Filho, Idiberto Zotarelli Rivas, Elsa Rivas, Jaime Carvalho, Katherine Athayde Teixeira de Dayer, Mohammad Reza Samadikuchaksaraei, Alí |
author2_role |
author author author author author author author author |
dc.subject.none.fl_str_mv |
Antibiotics COVID-19 Macrolides |
topic |
Antibiotics COVID-19 Macrolides |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
SARS-CoV-2 is a novel RNA coronavirus responsible of a deadly pandemic: the clinical illness COVID-19. With only one authorized drug for emergency use in critically ill patients: Remdesivir, there is not any other approved drug or vaccine yet with proven potential to overcome this infection. We exposed here many scientific evidences to support our novel idea that a macrolide, basically Clarithromycin, could be effective as a single agent for treatment and prophylaxis of COVID-19. Clarithromycin could change the history of this pandemic. It could reduce the costs of treatment and the potential adverse effects when combining more than one drug such as with Hydroxychloroquine. Clarithromycin treatment and prophylaxis as a single agent could be much more simple, safe and cheaper as giving Chloroquine or Hydroxychloroquine alone or in combination with Azithromycin as well as other therapeutic options. Fil: Mansilla, Eduardo. Universidad Nacional de La Plata. Facultad de Ciencias Médicas; Argentina Fil: Martínez, Ricardo Rangel. ExomePharma; México Fil: Marin, Gustavo Horacio. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de La Plata. Facultad de Ciencias Médicas; Argentina Fil: Filho, Idiberto Zotarelli. Faceres Medical School; Brasil Fil: Rivas, Elsa. Hospital de la Amistad Perú - Corea San Rosa II; Perú Fil: Rivas, Jaime. Hospital de la Amistad Perú - Corea San Rosa II; Perú Fil: Carvalho, Katherine Athayde Teixeira de. Research Institute Pelé Little Prince; Brasil Fil: Dayer, Mohammad Reza. Shahid Chamran University of Ahvaz; Irán Fil: Samadikuchaksaraei, Alí. Iran University of Medical Sciences; Irán |
description |
SARS-CoV-2 is a novel RNA coronavirus responsible of a deadly pandemic: the clinical illness COVID-19. With only one authorized drug for emergency use in critically ill patients: Remdesivir, there is not any other approved drug or vaccine yet with proven potential to overcome this infection. We exposed here many scientific evidences to support our novel idea that a macrolide, basically Clarithromycin, could be effective as a single agent for treatment and prophylaxis of COVID-19. Clarithromycin could change the history of this pandemic. It could reduce the costs of treatment and the potential adverse effects when combining more than one drug such as with Hydroxychloroquine. Clarithromycin treatment and prophylaxis as a single agent could be much more simple, safe and cheaper as giving Chloroquine or Hydroxychloroquine alone or in combination with Azithromycin as well as other therapeutic options. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-06 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/108870 Mansilla, Eduardo; Martínez, Ricardo Rangel; Marin, Gustavo Horacio; Filho, Idiberto Zotarelli; Rivas, Elsa; et al.; Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent; Scientific Research; Pharmacology & Pharmacy; 11; 6; 6-2020; 85-104 2157-9423 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/108870 |
identifier_str_mv |
Mansilla, Eduardo; Martínez, Ricardo Rangel; Marin, Gustavo Horacio; Filho, Idiberto Zotarelli; Rivas, Elsa; et al.; Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent; Scientific Research; Pharmacology & Pharmacy; 11; 6; 6-2020; 85-104 2157-9423 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.4236/pp.2020.116009 info:eu-repo/semantics/altIdentifier/url/https://www.scirp.org/journal/paperinformation.aspx?paperid=100971 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Scientific Research |
publisher.none.fl_str_mv |
Scientific Research |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844613458379669504 |
score |
13.070432 |